The Silicon Review ^Asia

Sun Pharmaceutical Industries, a Mumbai-based pharmaceutical company, has inked a deal with the subsidiary of China Medical System Holdings, a Chinese pharmaceutical company, ET reported.

The new licensing agreement will pave the way for Sun Pharma to work on the development and commercialization of dermatology products in Greater China, mainland China, Taiwan and special administrative regions of Hong Kong and Macau. The range of products for Sun Pharma includes Tildrakizumab, a biologic product for treating psoriatic arthritis and psoriasis along with an eye drop called Cyclosporine A 0.09 percent.

As per ET reports, The Chinese company will seal the deal initially with an upfront payment, royalties on net sales, sales milestones payments. The terms were not revealed by any of the companies.

The agreement will last for a period of 15 years from the first commercial sale of the two products in Greater China. And later on, the tenure may be increased to 3 years subject to specific conditions mentioned in the deal papers.

According to Sun Pharma, the new deal will help the company to enter the second largest pharmaceutical market in the world. The company is committed to expanding its dermatology franchises, with Tildrakizumab as its main product. The companycontinues to develop its therapeutic area of significant unmet need.

The new development will give confidence to other Pharmaceutical companies in India.